Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 393,131
  • Shares Outstanding, K 89,348
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,380 K
  • EBIT $ -51 M
  • EBITDA $ -51 M
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.03

Options Overview Details

View History
  • Implied Volatility 174.82% (-5.60%)
  • Historical Volatility 168.72%
  • IV Percentile 92%
  • IV Rank 27.33%
  • IV High 475.96% on 11/13/25
  • IV Low 61.57% on 02/19/25
  • Expected Move (DTE 12) 1.25 (28.40%)
  • Put/Call Vol Ratio 0.74
  • Today's Volume 2,747
  • Volume Avg (30-Day) 20,478
  • Put/Call OI Ratio 1.51
  • Today's Open Interest 208,698
  • Open Int (30-Day) 206,816
  • Expected Range 3.15 to 5.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.86 +53.85%
on 11/14/25
7.60 -42.11%
on 11/10/25
-2.91 (-39.81%)
since 11/05/25
3-Month
2.86 +53.85%
on 11/14/25
10.40 -57.69%
on 09/09/25
-5.00 (-53.19%)
since 09/05/25
52-Week
2.86 +53.85%
on 11/14/25
14.44 -69.53%
on 12/26/24
-3.20 (-42.11%)
since 12/05/24

Most Recent Stories

More News
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or “the Company”)...

AVXL : 4.40 (-1.12%)
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.40 (-1.12%)
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot

Anavex Life Sciences: Fiscal Q4 Earnings Snapshot

AVXL : 4.40 (-1.12%)
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Company to host a webcast t oday at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

AVXL : 4.40 (-1.12%)
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.40 (-1.12%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp.  ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors...

AVXL : 4.40 (-1.12%)
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.40 (-1.12%)
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s Alzheimer's Disease clinical trial results ...

AVXL : 4.40 (-1.12%)
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144 77.4 Weeks (17.8 Months) ‘time saved’ with oral blarcamesine compared to...

AVXL : 4.40 (-1.12%)
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 4.40 (-1.12%)

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

3rd Resistance Point 4.71
2nd Resistance Point 4.61
1st Resistance Point 4.51
Last Price 4.40
1st Support Level 4.31
2nd Support Level 4.21
3rd Support Level 4.11

See More

52-Week High 14.44
Fibonacci 61.8% 10.02
Fibonacci 50% 8.65
Fibonacci 38.2% 7.28
Last Price 4.40
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar